ESR1 and breast cancer: A recent report addressed the issue of anti-Her-2 agent resistance in breast cancers where targeting of FAK with FAK inhibitor PF4554878 and Her-2 with trastuzumab in ER+/Her-2+ patients showed synergistic effect on the suppression of cell growth and improved the response to trastuzumab [17].